United BioPharma won the “2020 National Talent Development Award"
United Biopharma (UBP) has received the "2020 National Talent Development Award", the highest honor in the field of human resources. This award was sponsored by the Taiwan Ministry of Labor and presented at a ceremony held at the Hilton Hotel in New Taipei City on December 9. UBP has undergone several stages of reviews and assessments and prevailed among 151 companies. UBP becomes the only company in the biotechnology industry to receive this prestigious award.
UBP is a biopharmaceutical company focusing on the development, manufacture, and commercialization of innovative antibody drugs in the areas of infectious diseases, immune disorders, and cancer. Our corporate mission is “We Care, We Invent, We Share” emphasizing “We care about patients’ unmet medical needs", “We develop innovative biological drugs to improve the quality of life”, and “We share the value with all stakeholders of the company, including patients, employees, shareholders, partners, and the general public".
Our Chairperson, Dr. Chang Yi Wang, states that “UBP focuses on the development of talented individuals who can identify with our corporate vision and culture and have the professional skills to achieve the company’s goals’ Based on a People-oriented, Team-oriented, and culture of Accountability, we build an integrated system for talent recruitment, training, evaluation, development, and retention, through internal reading clubs, job rotations, personal development plans, career development consultations, a dual-track promotion system, and other novel projects Reducing career development restrictions allows our employees to work in an environment where they can thrive, realize their potential and ultimately help propel our teams to move forward.“
We have established a Toastmaster Club as part of an international English speaking organization, and a free on-line English coach program, to strengthen colleagues’ foreign language skills. In addition to carrying out a series of talent development plans in the professional field, UBP also pays great attention to work-life balance. We have organized many health lectures, weight-loss competitions, parent-child activities, and outdoor activities to promote the physical and mental health of colleagues and family happiness.
On behalf of the company, Dr. Shugene Lynn, CEO and President of United Biopharma (first right, front row), received the "2020 National Talent Development Award for Small and Medium-sized Enterprises" from the Councilor of Executive Yuan Mr. Wan Yi Lin (first left, front row). Picture courtesy of United Biopharma.
Since its establishment, UBP has developed 6 monoclonal antibody product lines, which have entered phase I, phase II, and phase III clinical trials respectively. We will continue to strengthen our capability in R&D, clinical and manufacturing, and greatly improve through the highly integrated process to shorten the time to market of our pipeline products. UBP will be involved in the development of major pharmaceutical products to combat major diseases that endanger human health, such as the development of COVID-19 vaccines. Currently, UBP, as the sole contract manufacturer, is assisting United Biomedical, Asia (UBI Asia) to produce the main active ingredient sufficient for 100 million doses of COVID-19 vaccines.
UBP will continue to improve our Talent Quality-Management System, increase our talent pool, and continue to cultivate our people-oriented and team-accountability corporate culture. We will also continue to enhance the professional competence and humanistic qualities of colleagues, to accelerate the launch of new drugs that will benefit the health and well-being of the general public.
About United BioPharma
United BioPharma (UBP) is a clinical stage biopharmaceutical company, founded in 2013 as a spin-off from UBIAsia, its parent company. UBP is dedicated to research, development and manufacturing of novel monoclonal antibodies (mAbs) for infectious diseases, cancer and immune disorders. UBP’s Headquarters is located in Taiwan, with subsidiary companies in Shanghai and Yangzhou, China, and liaison offices in the U.S. The company has a global team, highly passionate about developing first-in-class, best-in-class therapeutic mAbs and delivering high-quality, affordable medicines to bring better life to the patients.